IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS
Publication
, Conference
Thompson, AJ; Clark, PJ; Tillmann, HL; Patel, K; Naggie, S; Poordad, FF; Lawitz, E; Bacon, BR; Vierling, JM; Noviello, S; Brass, CA; Muir, AJ ...
Published in: HEPATOLOGY
October 1, 2011
Duke Scholars
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2011
Volume
54
Start / End Page
436A / 437A
Location
San Francisco, CA
Publisher
WILEY-BLACKWELL
Conference Name
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics
Citation
APA
Chicago
ICMJE
MLA
NLM
Thompson, A. J., Clark, P. J., Tillmann, H. L., Patel, K., Naggie, S., Poordad, F. F., … Muir, A. J. (2011). IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS. In HEPATOLOGY (Vol. 54, pp. 436A-437A). San Francisco, CA: WILEY-BLACKWELL.
Thompson, Alexander J., Paul J. Clark, Hans L. Tillmann, Keyur Patel, Susanna Naggie, F Fred Poordad, Eric Lawitz, et al. “IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS.” In HEPATOLOGY, 54:436A-437A. WILEY-BLACKWELL, 2011.
Thompson AJ, Clark PJ, Tillmann HL, Patel K, Naggie S, Poordad FF, et al. IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS. In: HEPATOLOGY. WILEY-BLACKWELL; 2011. p. 436A-437A.
Thompson, Alexander J., et al. “IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS.” HEPATOLOGY, vol. 54, WILEY-BLACKWELL, 2011, pp. 436A-437A.
Thompson AJ, Clark PJ, Tillmann HL, Patel K, Naggie S, Poordad FF, Lawitz E, Bacon BR, Vierling JM, Noviello S, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG, Sulkowski MS, Muir AJ. IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS. HEPATOLOGY. WILEY-BLACKWELL; 2011. p. 436A-437A.
Published In
HEPATOLOGY
ISSN
0270-9139
Publication Date
October 1, 2011
Volume
54
Start / End Page
436A / 437A
Location
San Francisco, CA
Publisher
WILEY-BLACKWELL
Conference Name
62nd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD)
Related Subject Headings
- Gastroenterology & Hepatology
- 3204 Immunology
- 3202 Clinical sciences
- 1107 Immunology
- 1103 Clinical Sciences
- 1101 Medical Biochemistry and Metabolomics